ReviewCurrent allergy and asthma reports2023
Long-term Consequences of COVID-19: Chemosensory Disorders.
Review in Current allergy and asthma reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Neurological Manifestations of Long COVID: Current Evidence, Emerging Concepts, and Future Perspectives.Journal of clinical medicine · 2026Review
- Rhinoplasty and the 'Big Five' Model: The Impact of Patients' Personality Traits on Post-surgical Satisfaction Outcomes.Aesthetic plastic surgery · 2026Article
- Prevalence of and risk factors for post-coronavirus disease 2019 symptoms after severe acute respiratory syndrome coronavirus 2 infection in healthcare workers: A multicenter cross-sectional study in China.The Journal of international medical research · 2026Article
- The impact of COVID-19: consequences of a 3-Year struggle in Iran.BMC infectious diseases · 2025Article
- Symptoms and Otorhinolaryngological Sequalae in Long Covid.International archives of otorhinolaryngology · 2025Article
- Long-term self-reported symptoms and psychophysical tests in COVID-19 subjects experiencing persistent olfactory dysfunction: a 4-year follow-up study.Frontiers in neural circuits · 2025Article
- Maximizing Participation in Olfactory Training in a Sample with Post-COVID-19 Olfactory Loss.Brain sciences · 2024Article
- Long-term effects of SARS-CoV-2 infection in patients with and without chemosensory disorders at disease onset: a psychophysical and magnetic resonance imaging exploratory study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Article
- Impact of post-COVID-19 olfactory disorders on quality of life, hedonic experiences and psychiatric dimensions in general population.BMC psychiatry · 2024Article
- Efficacy of Palmitoylethanolamide and Luteolin Association on Post-Covid Olfactory Dysfunction: A Systematic Review and Meta-Analysis of Clinical Studies.Biomedicines · 2023Review
- Exploring the research landscape of COVID-19-induced olfactory dysfunction: A bibliometric study.Frontiers in neuroscience · 2023Review
- Article
- Long COVID-19 olfactory dysfunction: discrepancy between psychophysical tests and self-perception.Brazilian journal of otorhinolaryngologyObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewA number of sequelae after acute coronavirus disease 2019 (COVID-19) significantly affect the quality of life of patients. The chemosensory disorders including olfactory dysfunction (OD) and gustatory dysfunction (GD) are two of the commonest symptoms complained by patients with COVID-19. Although chemosensory function has been reported improved in over 60% of COVID-19 patients in a short time after acute infection, it may last as a major symptom for patients with long COVID-19. This narrative review discussed current literatures on OD and GD in long COVID-19 including the prevalence, risk factors, possible mechanisms, and potential therapies. RECENT
findingsAlthough the prevalence of OD and GD has declined continuously after acute COVID-19, a considerable number of patients had persistent chemosensory disorders 3 months to 2 years after symptom onset. Female gender, initial severity of dysfunction, nasal congestion, emotional distress and depression, and SARS-CoV-2 variants have been identified as risk factors for persistent OD and GD in long COVID-19. The pathogenesis of OD and GD in long COVID-19 remains unknown, but may be analogous to the persistent OD and GD post common respiratory viral infection. Corticosteroids and olfactory training might be a potential choice regarding the treatment of lasting OD and GD after SARS-CoV-2 infection; however, more studies are needed to prove it. OD and GD are common long-term consequences of COVID-19 and influenced by gender, initial severity of dysfunction, emotional distress and depression, and SARS-CoV-2 variants. More studies are needed to illustrate their pathogenesis and to establish therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.